|
1
|
Cabanillas ME, McFadden DG and Durante C:
Thyroid cancer. Lancet. 388:3316–2795. 2016. View Article : Google Scholar
|
|
2
|
Kushchayev SV, Kushchayeva YS, Tella SH,
Glushko T, Pacak K and Teytelboym OM: Medullary thyroid carcinoma:
An update on imaging. J Thyroid Res. 2019:18930472019. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Hao WJ, Zhang H, Yu Y, Zhao J, Ge ZJ, Ding
PX, Sun XX, Liu H, Wen SY and You J: Clinical significance and
cost-benefit analysis of serum calcitonin assay in diagnosis and
treatment of medullary thyroid carcinoma. Zhonghua Er Bi Yan Hou
Tou Jing Wai Ke Za Zhi. 54:506–509. 2019.(In Chinese). PubMed/NCBI
|
|
4
|
Kebebew E, Greenspan FS, Clark OH, Woeber
KA and Grunwell J: Extent of disease and practice patterns for
medullary thyroid cancer. J Am Coll Surg. 200:890–896. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Roman S, Lin R and Sosa JA: Prognosis of
medullary thyroid carcinoma: Demographic, clinical, and pathologic
predictors of survival in 1252 cases. Cancer. 107:2134–2142. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Kuo EJ, Sho S, Li N, Zanocco KA, Yeh MW
and Livhits MJ: Risk factors associated with reoperation and
disease-specific mortality in patients with medullary thyroid
carcinoma. JAMA Surg. 153:52–59. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Ceolin L, Duval M, Benini AF, Ferreira CV
and Maia AL: Medullary thyroid carcinoma beyond surgery: Advances,
challenges, and perspectives. Endocr Relat Cancer. 26:R499–R518.
2019. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Meijer JA, le Cessie S, van den Hout WB,
Kievit J, Schoones JW, Romijn JA and Smit JWA: Calcitonin and
carcinoembryonic antigen doubling times as prognostic factors in
medullary thyroid carcinoma: A structured meta-analysis. Clin
Endocrinol (Oxf). 72:534–542. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Zhang Y, Zhong Q, Chen X, Fang J and Huang
Z: Diagnostic value of microRNAs in discriminating malignant
thyroid nodules from benign ones on fine-needle aspiration samples.
Tumour Biol. 35:9343–9353. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Nishino M: Molecular cytopathology for
thyroid nodules: A review of methodology and test performance.
Cancer Cytopathol. 124:14–27. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Mohr AM and Mott JL: Overview of microRNA
biology. Semin Liver Dis. 35:3–11. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Liu X, Jiao Z, Chen H and Wang L: A
correlational study on miR-34s and cervical lesions. Eur J Gynaecol
Oncol. 39:786–789. 2018.
|
|
13
|
Lu TX and Rothenberg ME: MicroRNA. J
Allergy Clin Immunol. 141:1202–1207. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Tian T, Wang J and Zhou X: A review:
microRNA detection methods. Org Biomol Chem. 13:2226–2238. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Catalanotto C, Cogoni C and Zardo G:
microRNA in control of gene expression: An overview of nuclear
functions. Int J Mol Sci. 17:17122016. View Article : Google Scholar
|
|
16
|
Yeh M, Oh CS, Yoo JY, Kaur B and Lee TJ:
Pivotal role of microRNA-138 in human cancers. Am J Cancer Res.
9:1118–1126. 2019.PubMed/NCBI
|
|
17
|
Humphries B, Wang Z and Yang C: microRNA
regulation of epigenetic modifiers in breast cancer. Cancers
(Basel). 11:8972019. View Article : Google Scholar
|
|
18
|
Chu YH, Hardin H, Schneider DF, Chen H and
Lloyd RV: microRNA-21 and long non-coding RNA MALAT1 are
overexpressed markers in medullary thyroid carcinoma. Exp Mol
Pathol. 103:229–236. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Hou W, Zhang H, Bai X, Liu X, Yu Y, Song L
and Du Y: Suppressive role of miR-592 in breast cancer by
repressing TGF-β2. Oncol Rep. 38:3447–3454. 2017.PubMed/NCBI
|
|
20
|
Slattery ML, Mullany LE, Sakoda LC, Wolff
RK, Samowitz WS and Herrick JS: Dysregulated genes and miRNAs in
the apoptosis pathway in colorectal cancer patients. Apoptosis.
23:237–250. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Xu Y, Li K, Wang SB and Yang SG: Mir-592
functions as a tumor suppressor in acute myeloid leukemia by
targeting ROCK1 and predicts patients' prognosis. Eur Rev Med
Pharmacol Sci. 23:1610–1619. 2019.PubMed/NCBI
|
|
22
|
Gao S, Chen J, Wang Y, Zhong Y, Dai Q,
Wang Q and Tu J: MiR-592 suppresses the development of glioma by
regulating rho-associated protein kinase. Neuroreport.
29:1391–1399. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Clough E and Barrett T: The gene
expression omnibus database. Methods Mol Biol. 1418:93–110. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Ashburner M, Ball CA, Blake JA, Botstein
D, Butler H, Cherry JM, Davis AP, Dolinski K, Dwight SS, Eppig JT,
et al: Gene ontology: Tool for the unification of biology. The gene
ontology consortium. Nat Genet. 25:25–29. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
The Gene Ontology Consortium, . The gene
ontology resource: 20 years and still going strong. Nucleic Acids
Res. 47:D330–D338. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Nikiforova M N, Tseng G C, Steward D, et
al: MicroRNA Expression Profiling of Thyroid Tumors: Biological
Significance and Diagnostic Utility. Journal of Clinical
Endocrinology & Metabolism. 93:1600–1608. 2008. View Article : Google Scholar
|
|
27
|
Kanehisa M, Sato Y, Furumichi M, Morishima
K and Tanabe M: New approach for understanding genome variations in
KEGG. Nucleic Acids Res. 47:D590–D595. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Kanehisa M: Toward understanding the
origin and evolution of cellular organisms. Protein Sci.
28:1947–1951. 2019. View
Article : Google Scholar : PubMed/NCBI
|
|
29
|
Besso MJ, Rosso M, Lapyckyj L, Moiola CP,
Matos ML, Mercogliano MF, Schillaci R, Reventos J, Colas E,
Gil-Moreno A, et al: FXYD5/dysadherin, a biomarker of endometrial
cancer myometrial invasion and aggressiveness: Its relationship
with TGF-β1 and NF-κB pathways. Front Oncol. 9:13062019. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Cari L, Nocentini G, Migliorati G and
Riccardi C: Potential effect of tumor-specific treg-targeted
antibodies in the treatment of human cancers: A bioinformatics
analysis. Oncoimmunology. 7:e13877052018. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Li C, Zhou D, Jiang X, Liu M, Tang H and
Mei Z: Identifying hepatocellular carcinoma-related hub genes by
bioinformatics analysis and CYP2C8 is a potential prognostic
biomarker. Gene. 698:9–18. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Zhu G, Xie L and Miller D: Expression of
microRNAs in thyroid carcinoma. Methods Mol Biol. 1617:261–280.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Orlandella FM, Mariniello RM, Iervolino
PLC, Imperlini E, Mandola A, Verde A, De Stefano AE, Pane K,
Franzese M, Esposito S, et al: miR-650 promotes motility of
anaplastic thyroid cancer cells by targeting PPP2CA. Endocrine.
65:582–594. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Zhao P, Ma W, Hu Z, Zhang Y, Zhang S and
Wang Y: Up-regulation of miR-340-5p promotes progression of thyroid
cancer by inhibiting BMP4. J Endocrinol Invest. 41:1165–1172. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Liu X, Fu Y, Zhang G, Zhang D, Liang N, Li
F, Li C, Sui C, Jiang J, Lu H, et al: Mir-424-5p promotes anoikis
resistance and lung metastasis by inactivating hippo signaling in
thyroid cancer. Mol Ther Oncolytics. 15:248–260. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Zhang W, Ji W and Zhao X: Mir-155 promotes
anaplastic thyroid cancer progression by directly targeting socs1.
BMC Cancer. 19:10932019. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Gong Y, Wu W, Zou X, Liu F, Wei T and Zhu
J: Mir-26a inhibits thyroid cancer cell proliferation by targeting
arpp19. Am J Cancer Res. 8:1030–1039. 2018.PubMed/NCBI
|
|
38
|
Han J, Zhang M, Nie C, Jia J, Wang F, Yu
J, Bi W, Liu B, Sheng R, He G, et al: Mir-215 suppresses papillary
thyroid cancer proliferation, migration, and invasion through the
AKT/GSK-3β/Snail signaling by targeting ARFGEF1. Cell Death Dis.
10:1952019. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Liu H, Deng H, Zhao Y, Li C and Liang Y:
Lncrna xist/miR-34a axis modulates the cell proliferation and tumor
growth of thyroid cancer through met-Pi3K-Akt signaling. J Exp Clin
Cancer Res. 37:2792018. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Wang P, Gu J, Wang K, Shang J and Wang W:
miR-206 inhibits thyroid cancer proliferation and invasion by
targeting RAP1B. J Cell Biochem. 120:18927–18936. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Saiselet M, Pita JM, Augenlicht A, Dom G,
Tarabichi M, Fimereli D, Dumont JE, Detours V and Maenhaut C: miRNA
expression and function in thyroid carcinomas: A comparative and
critical analysis and a model for other cancers. Oncotarget.
7:52475–52492. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Chu YH and Lloyd RV: Medullary thyroid
carcinoma: Recent advances including microRNA expression. Endocr
Pathol. 27:312–324. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Abraham D, Jackson N, Gundara JS, Zhao JT,
Gill AJ, Delbridge L, Robinson BG and Sidhu SB: microRNA profiling
of sporadic and hereditary medullary thyroid cancer identifies
predictors of nodal metastasis, prognosis, and potential
therapeutic targets. Clin Cancer Res. 17:4772–4781. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Hudson J, Duncavage E, Tamburrino A,
Salerno P, Xi L, Raffeld M, Moley J and Chernock RD: Overexpression
of miR-10a and miR-375 and downregulation of YAP1 in medullary
thyroid carcinoma. Exp Mol Pathol. 95:62–67. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Yerukala Sathipati S and Ho SY:
Identifying a miRNA signature for predicting the stage of breast
cancer. Sci Rep. 8:161382018. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Liu M, Zhi Q, Wang W, Zhang Q, Fang T and
Ma Q: Up-regulation of miR-592 correlates with tumor progression
and poor prognosis in patients with colorectal cancer. Biomed
Pharmacother. 69:214–220. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Fu Q, Du Y, Yang C, Zhang D, Zhang N, Liu
X, Cho WC and Yang Y: An oncogenic role of miR-592 in tumorigenesis
of human colorectal cancer by targeting forkhead box o3a (FoxO3A).
Expert Opin Ther Targets. 20:771–782. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Lv Z, Rao P and Li W: MiR-592 represses
FOXO3 expression and promotes the proliferation of prostate cancer
cells. Int J Clin Exp Med. 8:15246–15257. 2015.PubMed/NCBI
|
|
49
|
He Y, Ge Y, Jiang M, Zhou J, Luo D, Fan H,
Shi L, Lin L and Yang L: MiR-592 promotes gastric cancer
proliferation, migration, and invasion through the Pi3K/Akt and
MAPK/ERK signaling pathways by targeting spry2. Cell Physiol
Biochem. 47:1465–1481. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Bragelmann J, Klümper N, Offermann A, von
Mässenhausen A, Böhm D, Deng M, Queisser A, Sanders C, Syring I,
Merseburger AS, et al: Pan-cancer analysis of the mediator complex
transcriptome identifies CDK19 and CDK8 as therapeutic targets in
advanced prostate cancer. Clin Cancer Res. 23:1829–1840. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
51
|
McDermott MS, Chumanevich AA, Lim CU,
Liang J, Chen M, Altilia S, Oliver D, Rae JM, Shtutman M, Kiaris H,
et al: Inhibition of CDK8 mediator kinase suppresses estrogen
dependent transcription and the growth of estrogen receptor
positive breast cancer. Oncotarget. 8:12558–12575. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Liang J, Chen M, Broude EV and Roninson
IB: Role of transcription-regulating kinase CDK8 in colon cancer
metastasis. Oncotarget. 10:622–623. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Philip S, Kumarasiri M, Teo T, Yu M and
Wang S: Cyclin-dependent kinase 8: A new hope in targeted cancer
therapy? J Med Chem. 61:5073–5092. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Crown J: CDK8: A new breast cancer target.
Oncotarget. 8:14269–14270. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Song W, Wu S, Wu Q, Zhou L, Yu L, Zhu B
and Gong X: The microRNA-141-3p/CDK8 pathway regulates the
chemosensitivity of breast cancer cells to trastuzumab. J Cell
Biochem. 120:14095–14106. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Wei R, Kong L, Xiao Y, Yuan H, Song Y,
Wang J, Yu H, Mao S and Xu W: CDK8 regulates the angiogenesis of
pancreatic cancer cells in part via the CDK8-β-catenin-klf2 signal
axis. Exp Cell Res. 369:304–315. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Xing S, Xu Q, Fan X, Wu S and Tian F:
Downregulation of miR-138-5p promotes non-small cell lung cancer
progression by regulating CDK8. Mol Med Rep. 20:5272–5278.
2019.PubMed/NCBI
|
